Kineta Completes Reverse Merger with Yumanity Therapeutics

SEATTLE, Dec. 19 (Korea Bizwire) — Kineta, Inc. (“Kineta” or the “Company”), a clinical-stage biotechnology company focused on developing next-generation immunotherapies to address cancer immune resistance, announced today the completion of its reverse merger with Yumanity Therapeutics, Inc. (“Yumanity”). The combined company will operate under the name Kineta, Inc. and its shares will commence trading [...]

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

BOSTON, Aug. 29 (Korea Bizwire) — Yumanity Therapeutics, Inc. (“Yumanity”) (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced the filing of a registration statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (the “SEC”). The Registration Statement contains [...]